Substantial revenue and profit growth driven by selexipag-related income and other factors

「Revenue increased 6.6% year on year to ¥170.771 billion. In terms of profit, operating profit increased slightly, by 0.1%, to ¥35.496 billion, mainly due to higher revenue and an increase in other income. Profit before tax increased 0.9% to ¥36.462 billion, while profit for the year attributable to owners of the parent decreased 8.7% to ¥29.721 billion due to an increase in income tax expense.」

「For the interim consolidated accounting period, revenue increased 0.4% year on year to ¥79.647 billion. In terms of profit, operating profit increased 9.6% to ¥19.580 billion, mainly due to decreases in research and development expenses and other expenses. Interim profit before tax increased 10.1% to ¥20.029 billion, while interim profit attributable to owners of the parent decreased 3.7% to ¥15.760 billion due to an increase in income tax expense.」

「In addition, products including Vyxeos, a treatment for high-risk acute myeloid leukemia launched in May 2024, contributed to an 8.1% year-on-year increase in revenue to ¥160.232 billion. In terms of profit, operating profit increased 6.5% to ¥35.450 billion, mainly due to higher revenue and a decrease in the cost-of-sales ratio resulting from the sales mix. Profit before tax increased 7.5% to ¥36.135 billion, and profit for the year attributable to owners of the parent increased 25.9% to ¥32.558 billion.」

「For the interim consolidated accounting period, revenue increased 8.2% year on year to ¥79.332 billion. In terms of profit, operating profit fell 14.4% year on year to ¥17.867 billion due mainly to increases in selling, general and administrative expenses and research and development expenses. Interim profit before tax decreased 13.9% to ¥18.198 billion, while interim profit attributable to owners of the parent increased 1.2% to ¥16.373 billion, partly due to a decrease in income tax expense.」

「Revenue increased 2.8% from the previous fiscal year to ¥148.255 billion. In terms of profit, higher revenue and a lower cost of sales ratio due to the sales mix and other factors resulted in operating profit rising 10.8% to ¥33.295 billion, profit before tax rising 10.3% to ¥33.616 billion, and profit attributable to owners of the parent rising 13.3% to ¥25.851 billion.」

「During the third quarter, revenue increased 2.6% year on year to ¥112.728 billion. Higher revenue and a lower cost of sales ratio due to the sales mix and other factors resulted in operating profit rising 8.8% to ¥30.45 billion, profit before tax rising 9.0% to ¥30.973 billion, and profit attributable to owners of the parent rising 5.9% to ¥24.002 billion.」

「During the second quarter, revenue increased 3.1% year on year to ¥73.314 billion. Higher revenue and a lower cost of sales ratio due to the sales mix and other factors resulted in operating profit rising 9.0% to ¥20.878 billion, profit before tax rising 9.0% to ¥21.146 billion, and profit attributable to owners of the parent rising 6.3% to ¥16.176 billion.」

「During the first quarter, revenue increased 3.9% year on year to ¥37.012 billion. Higher revenue and a lower cost of sales ratio due to the sales mix and other factors resulted in operating profit rising 8.6% to ¥11.163 billion, profit before tax rising 8.8% to ¥11.44 billion, and profit attributable to owners of the parent rising 6.1% to ¥8.749 billion.」

「The Group’s results benefited from growth in the pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension treatment Uptravi, royalty income from overseas sales of the product, and the Duchenne muscular dystrophy treatment Viltepso. Revenue increased 4.9% from the previous fiscal year to ¥144.175 billion. In terms of profit, the reversal of the prior-year one-time income from the sale of a priority review voucher and other factors caused operating profit to decline 8.8% to ¥30.049 billion, profit before tax to decline 8.4% to ¥30.489 billion, and profit attributable to owners of the parent to decline 8.7% to ¥22.812 billion.」

「During the third quarter, revenue increased 3.4% year on year to ¥109.919 billion. In terms of profit, the reversal of the prior-year one-time income from the sale of a priority review voucher, the higher cost of sales ratio due to the sales mix and other factors caused operating profit to decline 7.8% to ¥27.987 billion, profit before tax to decline 7.5% to ¥28.422 billion, and profit attributable to owners of the parent to decline 1.7% to ¥22.674 billion.」

「During the second quarter, revenue declined 0.6% year on year to ¥71.136 billion, partly because of the reversal of the prior-year one-time income from the sale of a priority review voucher. In terms of profit, lower revenue and a higher cost of sales ratio due to the sales mix and other factors caused operating profit to decline 12.1% to ¥19.161 billion, profit before tax to decline 11.9% to ¥19.398 billion, and profit attributable to owners of the parent to decline 7.9% to ¥15.222 billion.」

「During the first quarter, revenue declined 13.1% year on year to ¥35.619 billion, partly because of the reversal of the prior-year one-time income from the sale of a priority review voucher. In terms of profit, lower revenue and a higher cost of sales ratio due to the sales mix and other factors caused operating profit to decline 37.9% to ¥10.276 billion, profit before tax to decline 37.3% to ¥10.514 billion, and profit attributable to owners of the parent to decline 34.5% to ¥8.249 billion.」

「During the third quarter, revenue increased 15.7% year on year to ¥106.218 billion. Higher revenue and a lower cost of sales ratio due to the sales mix resulted in operating profit rising 44.0% to ¥29.321 billion, ordinary profit rising 45.4% to ¥30.563 billion, and profit attributable to owners of the parent rising 49.9% to ¥22.606 billion.」

「During the second quarter, revenue increased 23.8% year on year to ¥71.568 billion. Higher revenue and a lower cost of sales ratio due to the sales mix resulted in operating profit rising 93.0% to ¥21.504 billion, ordinary profit rising 97.8% to ¥22.25 billion, and profit attributable to owners of the parent rising 105.1% to ¥16.561 billion.」

「During the first quarter, revenue increased 37.6% year on year to ¥41.157 billion. Higher revenue and a lower cost of sales ratio due to the sales mix resulted in operating profit rising 118.6% to ¥16.448 billion, ordinary profit rising 114.9% to ¥16.598 billion, and profit attributable to owners of the parent rising 111.5% to ¥12.341 billion.」

「Royalty income from overseas sales of the proprietary pulmonary arterial hypertension treatment Uptravi, growth in the domestic portfolio of new pharmaceutical products, Uptravi milestone income and other factors contributed to a 4.5% year-on-year increase in revenue to ¥121.885 billion. In terms of profit, higher revenue and a lower cost of sales ratio due to the sales mix resulted in operating profit rising 20.6% to ¥26.134 billion, ordinary profit rising 19.2% to ¥26.76 billion, and profit attributable to owners of the parent rising 22.7% to ¥20.702 billion.」

「During the nine months ended this third quarter, the domestic pharmaceutical and functional food businesses continued to be affected by COVID-19, but growth in royalty income from overseas sales of the proprietary pulmonary arterial hypertension treatment Uptravi, sales of the new product portfolio and Uptravi milestone income contributed to a 4.2% year-on-year increase in revenue to ¥91.837 billion. Lower cost of sales due to higher revenue and the sales mix resulted in operating profit rising 31.7% to ¥20.362 billion, ordinary profit rising 29.2% to ¥21.023 billion, and profit attributable to owners of the parent rising 26.9% to ¥15.085 billion.」

「During the six months ended this second quarter, the domestic pharmaceutical and functional food businesses were affected by COVID-19, but growth in royalty income from overseas sales of the proprietary pulmonary arterial hypertension treatment Uptravi and other factors drove revenue up 0.8% year on year to ¥57.817 billion. Although research and development expenses increased, higher revenue, a lower cost of sales ratio due to the sales mix, and lower expenses resulting from restrictions on activities due to COVID-19 caused operating profit to rise 1.0% to ¥11.14 billion, while ordinary profit was broadly flat year on year at ¥11.248 billion and profit attributable to owners of the parent declined 2.6% to ¥8.073 billion.」

「During the first quarter, the domestic pharmaceutical and functional food businesses were affected by COVID-19, but growth in royalty income from overseas sales of the proprietary pulmonary arterial hypertension treatment Uptravi and other factors drove revenue up 1.8% year on year to ¥29.913 billion. In terms of profit, higher revenue, a lower cost of sales ratio due to the sales mix, and lower expenses resulting from restrictions on activities due to COVID-19 caused operating profit to rise 16.6% to ¥7.522 billion, ordinary profit to rise 17.3% to ¥7.723 billion, and profit attributable to owners of the parent to rise 17.9% to ¥5.835 billion.」

「As a result, although income from industrial property rights and other sources declined from the previous fiscal year, when milestone income from the pulmonary arterial hypertension treatment Uptravi was recorded, revenue benefited from growth in the domestic portfolio of new pharmaceutical products and co-promotion income and increased 1.7% year on year to ¥116.637 billion. In terms of profit, despite a higher cost of sales ratio due to the drug price revision and other factors, higher revenue and other factors resulted in operating profit rising 5.0% to ¥21.668 billion, ordinary profit rising 4.2% to ¥22.442 billion, and profit attributable to owners of the parent rising 3.5% to ¥16.866 billion.」

「For the cumulative third quarter of the current consolidated fiscal year, revenue increased 1.3% year on year to ¥88.113 billion. On the earnings side, the reversal of milestone income from Uptravi recorded in the same period of the previous year and the increase in the cost of sales ratio due to the drug-price revision and other factors resulted in operating profit of ¥15.466 billion, down 5.9% year on year, ordinary profit of ¥16.277 billion, down 5.6%, and quarterly net income attributable to owners of the parent of ¥11.886 billion, down 6.4%.」

「During the six months ended this second quarter, revenue increased 7.3% year on year to ¥57.387 billion. Higher revenue and a lower cost of sales ratio due to the sales mix resulted in operating profit rising 45.7% to ¥11.025 billion, ordinary profit rising 37.5% to ¥11.271 billion, and profit attributable to owners of the parent rising 37.3% to ¥8.291 billion.」

「During the first quarter, revenue increased 5.7% year on year to ¥29.391 billion. In terms of profit, higher revenue and a lower cost of sales ratio due to the sales mix resulted in operating profit rising 33.1% to ¥6.453 billion, ordinary profit rising 23.8% to ¥6.585 billion, and profit attributable to owners of the parent rising 24.9% to ¥4.951 billion.」

「As a result, the Group’s results benefited from growth in the domestic portfolio of new pharmaceutical products, co-promotion income, royalty income from overseas sales of the proprietary pulmonary arterial hypertension treatment Uptravi, milestone income and other factors. Revenue increased 13.1% from the previous consolidated fiscal year to ¥114.716 billion. Although payments of upfront fees under licensing agreements, research and development expenses related to the progress of clinical trials, and promotional expenses for the new product portfolio increased, higher revenue drove operating profit up 20.9% to ¥20.644 billion, ordinary profit up 23.4% to ¥21.54 billion, and profit attributable to owners of the parent up 25.9% to ¥16.302 billion, all representing substantial increases.」

「During the nine months ended this third quarter, revenue increased 12.0% year on year to ¥87.019 billion. Although research and development expenses related to the progress of clinical trials and promotional expenses for the new product portfolio increased, higher revenue resulted in operating profit rising 7.1% to ¥16.435 billion, ordinary profit rising 7.9% to ¥17.244 billion, and profit attributable to owners of the parent rising 8.9% to ¥12.698 billion.」

「For the cumulative second quarter of the current consolidated fiscal year, revenue increased 7.7% year on year to ¥53.497 billion. On the earnings side, the increase in the cost of sales ratio following the drug-price revision, higher R&D expenses as clinical trials progressed, and increased promotional expenses for new product lines resulted in operating profit of ¥7.569 billion, down 18.3% year on year, ordinary profit of ¥8.196 billion, down 15.3%, and quarterly net income attributable to owners of the parent of ¥6.037 billion, down 13.7%.」

「During the first quarter, revenue increased 14.8% year on year to ¥27.798 billion. In terms of profit, higher cost of sales due to the drug price revision, increased research and development expenses as clinical trials progressed, and higher promotional expenses for the new product portfolio caused operating profit to decline 3.3% to ¥4.846 billion and ordinary profit to decline 1.1% to ¥5.32 billion, while profit attributable to owners of the parent increased 0.1% to ¥3.964 billion.」

「During the nine months ended this third quarter, royalty income from overseas sales of the licensed proprietary drug Uptravi and co-promotion income increased substantially, in addition to growth in the domestic portfolio of new pharmaceutical products. However, revenue increased only 1.9% year on year to ¥77.73 billion because the prior-year period included income from the settlement of past-due charges for Uptravi active pharmaceutical ingredients, which did not recur. In terms of profit, the reversal of that effect and increases in selling, general and administrative expenses and research and development expenses caused operating profit to decline 12.3% to ¥15.342 billion, ordinary profit to decline 15.0% to ¥15.975 billion, and profit attributable to owners of the parent to decline 12.2% to ¥11.66 billion.」

「During the six months ended this second quarter, consolidated revenue increased 11.6% year on year to ¥49.66 billion, supported by growth in the domestic portfolio of new pharmaceutical products and royalty income from overseas sales of the proprietary drug Uptravi. Operating profit rose 42.7% to ¥9.266 billion, ordinary profit rose 57.9% to ¥9.678 billion, and profit attributable to owners of the parent rose 56.1% to ¥6.998 billion.」

「During the first quarter, consolidated revenue increased 2.0% year on year to ¥24.212 billion. In terms of profit, although promotional expenses for the new product portfolio increased, higher revenue and the deferral of some research and development expenses to the second quarter and beyond resulted in operating profit rising 13.3% to ¥5.012 billion, ordinary profit rising 30.0% to ¥5.381 billion, and profit attributable to owners of the parent rising 28.6% to ¥3.959 billion.」

「The Group’s results benefited from growth in the domestic portfolio of new pharmaceutical products, upfront income following European approval of the licensed proprietary drug Uptravi, royalty income from overseas sales and active pharmaceutical ingredient sales. Revenue increased 17.3% from the previous consolidated fiscal year to ¥98.781 billion. Operating profit rose 78.7% to ¥15.28 billion, ordinary profit rose 81.4% to ¥16.244 billion, and profit attributable to owners of the parent rose 85.3% to ¥11.749 billion, all representing substantial increases.」

「During the nine months ended this third quarter, consolidated results benefited from growth in the domestic portfolio of new pharmaceutical products, upfront income following European approval of the licensed proprietary drug selexipag, royalty income from overseas sales and sales of active pharmaceutical ingredients. Revenue increased 20.2% year on year to ¥76.26 billion. In terms of profit, in addition to higher revenue, some research and development expenses, selling expenses and general and administrative expenses were deferred to the fourth quarter. As a result, operating profit rose 153.3% to ¥17.496 billion, ordinary profit rose 158.6% to ¥18.792 billion, and profit attributable to owners of the parent rose 164.6% to ¥13.275 billion, all representing substantial increases.」